Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
21 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/21/2966150/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-Resubmission-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Systemic-Treatment-for-Unresectab.html
23 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/23/2951315/0/en/Elevar-Therapeutics-Resubmits-New-Drug-Application-to-FDA-for-Combination-of-Camrelizumab-plus-Rivoceranib-as-First-Line-Treatment-Option-for-Unresectable-Hepatocellular-Carcinoma-.html
12 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/12/2945136/0/en/Elevar-Therapeutics-Reports-Advances-in-HCC-and-Other-Oncology-Clinical-Programs-for-Rivoceranib-Plus-Camrelizumab-at-the-European-Society-for-Medical-Oncology-Congress-2024.html
01 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/01/2922906/0/en/Elevar-Therapeutics-Granted-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-First-Line-Systemic-Therapy-for-Unresectable-Hepatocellular-Carcinoma.html
10 Jul 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/elevar-hengrui-eye-quick-refile-pd-1-liver-cancer-combo-after-surprise-fda-rejection
09 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/en/news-release/2024/07/09/2910288/0/en/Elevar-Therapeutics-Reports-Plans-for-Near-Term-Resubmission-of-NDA-for-First-Line-Treatment-Option-for-Unresectable-Hepatocellular-Carcinoma-Following-Type-A-FDA-Meeting.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?